RETA - Reata Pharmaceuticals Inc Stock Price, Fair Value and News

Market Closed

RETA Stock Valuation Analysis

Valuation

Max Portfolio %

RETA Price Action

RETA RSI Chart

RETA Stock Valuation Analysis

Valuation

Max Portfolio %

RETA Valuation

RETA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RETA Fundamentals

RETA Revenue

RETA Earnings

RETA Profitability

RETA Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	11.5M	10.0M	3.1M	2.2M
2021	8.6M	7.8M	13.7M	11.5M
2020	20.1M	15.3M	8.5M	9.0M
2019	29.0M	29.2M	32.3M	26.5M
2018	67.7M	62.5M	55.1M	53.6M
2017	50.1M	50.6M	50.6M	48.1M
2016	49.8M	49.8M	49.9M	49.9M
2015	51.5M	51.1M	50.7M	50.3M
2014	0	0	0	52.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

CEO	Mr. J. Warren Huff
WEBSITE	reatapharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	321